关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 74,375,494 股，占公司总股本 的 7.18%；王海波先生持有公司股份 56,099,327 股，占公司总股本的 5.41%。上 述股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股 份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-024 上海复旦张江生物医药股份有限公司 集中竞价减持计划的实施结果情况 1、2025 年 6 月 23 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2025-018）。因自 身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公司股份不超过 10,365 ...

Core Viewpoint - The Hong Kong innovative drug-themed ETFs have shown significant performance, with the top 10 ETFs all increasing by over 5%, indicating strong market interest in the innovative drug sector [1][2]. Group 1: ETF Performance - The Hang Seng Innovative Drug ETF (520500) led the gains with a 5.73% increase, reaching a value of 1.864 [2]. - Other notable ETFs include the Hong Kong Innovative Drug ETF with a 5.28% increase and the Hong Kong Stock Connect Innovative Drug ETF with a 5.26% increase [2]. - Among the top-performing stocks, Kangfang Biotech (09926.HK) and BeiGene (06160.HK) both rose over 10%, while Innovent Biologics (01801.HK) and CSPC Pharmaceutical Group (01093.HK) increased by over 3% [2]. Group 2: Market Trends - A total of 25 ETFs have increased by over 40% this year, with 24 of them being related to the Hong Kong biopharmaceutical theme, highlighting the sector's strong performance [3]. - The Hong Kong Innovative Drug Index has risen over 70% since the beginning of the year, significantly outperforming the Hang Seng Index, reflecting high market recognition of the innovative drug industry [4]. Group 3: Policy and Market Drivers - The continuous optimization of the policy environment has positively impacted market sentiment, with the National Healthcare Security Administration initiating adjustments to the 2025 National Medical Insurance Directory, which includes innovative drugs with high clinical value [5]. - The trend of Chinese innovative drugs going global has reached historic breakthroughs, indicating an increase in global competitiveness [5]. - Fund managers express optimism about the innovative drug sector, citing strong clinical data and ongoing product commercialization as key factors for future performance [6].

复旦张江公告，股东杨宗孟于2025年7月14日至2025年7月16日期间通过集中竞价交易方式累计减持公司 股份数量为1036.57万股，减持股份数量占公司总股本比例为1.00%。王海波先生于2025年7月14日至 2025年7月15日通过集中竞价交易方式累计减持公司股份数量427.07万股，减持股份数量占公司总股本 比例为0.41%，并决定提前终止减持计划。杨宗孟先生减持后持股数量为6400.98万股，持股比例为 6.18%；王海波先生减持后持股数量为5182.86万股，持股比例为5.00%。 ...

最近一个月来，复旦张江累计涨幅14.31%，今年来累计涨幅57.99%，跑赢恒生指数22.22%的涨幅。 7月17日，截至港股收盘，恒生指数下跌0.08%，报24498.95点。复旦张江（01349.HK）收报4.4港元/ 股，上涨14.29%，成交量3.73亿股，成交额17.44亿港元，振幅34.81%。 2025年7月15日，杨宗孟于2025-07-15减持387.8万股，每股均价8.8人民币，最新持股数目6760万股，最 新持股比例9.51% （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 本文源自：金融界 作者：行情君 财务数据显示，截至2025年3月31日，复旦张江实现营业总收入1.8亿元，同比增长21.85%；归母净利润 266.51万元，同比增长13.53%；毛利率91.08%，资产负债率8.82%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为2.45倍，行业中值6.93倍。复旦张江市盈 率92.37倍，行业排名第73位；其他精优药业（00858.HK）为0.9倍、金斯瑞生物科技（01548.H ...

Group 1 - The core viewpoint of the article highlights the significant rise in the stock prices of several pharmaceutical companies listed on the Hong Kong Stock Exchange, indicating a positive trend in the sector [1] Group 2 - Company "三叶草生物" (Clover Biopharmaceuticals) experienced a stock price increase of 28.17% [1] - Company "复旦张江" (Fudan Zhangjiang) saw a rise of 22.86% in its stock price [1] - Company "康诺亚-B" (CanSino Biologics) reported an increase of 11.10% in its stock price [1] - Company "康方生物" (Kangfang Biologics) had a stock price increase of 11.03% [1]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market, particularly the healthcare sector, is experiencing a strong rally driven by the revaluation of innovative drug companies, with significant increases in stock prices and ETF performance [1][2]. - The CSI Hong Kong Innovative Drug Index rose by 4.23%, with notable gains from companies such as Fudan Zhangjiang (over 18% increase), Lepu Biopharma-B (over 10% increase), and Kangfang Biotech (over 9% increase) [1]. - The Hong Kong Innovative Drug 50 ETF (513780) saw a 3.57% increase, with a trading volume exceeding 200 million yuan within the first half hour of trading [1]. Group 2 - According to Jiao Yin International, the current innovative drug market in Hong Kong is driven by value re-evaluation, with attractive valuations compared to U.S. counterparts, as leading innovative drug companies have a forward 12-month price-to-sales ratio around 3 times, lower than the U.S. average of 4 times [2]. - Donghai Securities noted that the domestic innovative drug sector has seen increased activity this year, with high-value business development transactions and rising R&D investments, indicating a potential systematic recovery in the CXO and upstream life sciences sectors [2]. - Investment opportunities are suggested in various sub-sectors including CXO, innovative drugs, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [2].

Group 1 - The National Healthcare Security Administration has initiated the 11th batch of centralized drug procurement, with 55 drug varieties included in the reporting range [1] - The procurement principles emphasize maintaining clinical stability, ensuring quality, preventing collusion, and avoiding excessive competition, with a focus on non-new drugs [1] - The current valuation of leading innovative drug companies in Hong Kong is attractive, with a forward 12-month price-to-sales ratio around 3 times, lower than the US average of 4 times [1] Group 2 - Domestic interest in innovative drugs has surged this year, with significant BD transactions and increased R&D investment from innovative drug companies [2] - The Hong Kong pharmaceutical and biotechnology sector has shown strength, with notable stock price increases for companies like 开拓药业 (over 20%) and 复旦张江 (over 20%) [2] - The CXO and upstream life sciences sectors are expected to stabilize and improve, presenting systemic recovery opportunities [2]

Group 1: Fudan Zhangjiang - Fudan Zhangjiang is advancing its DC platform and photodynamic technology platform, with multiple antibody-drug conjugates in various clinical stages for treating cancers such as triple-negative breast cancer, bladder cancer, and gastric cancer [1] - The company is conducting Phase III clinical studies for anti-Trop2 antibody-drug conjugates and has completed the first subject enrollment for a clinical trial involving aminolevulinic acid granules for non-muscle invasive bladder cancer [1] - Fudan Zhangjiang plans to increase R&D investment to further promote the progress of its research projects [1] Group 2: Xiangyu Medical - Xiangyu Medical's research indicates a clear and significant demand for non-invasive brain-machine interfaces in rehabilitation, sleep monitoring, and attention enhancement [2] - The company has developed two EEG collection devices that have received Class II medical device registration and expects to obtain multiple registrations for brain-machine interface products in the second half of the year [2] - Xiangyu Medical's sales strategy involves starting with top-tier hospitals and gradually expanding to lower-tier hospitals and community health centers, with plans to enter the home market [2]

Core Points - The report indicates that Wang Haibo has reduced his shareholding in Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. from 5.41% to 5.00%, marking the first time his holding has fallen below 5% [1][4] - The reduction was executed through centralized bidding, with a total of 4,270,722 shares sold, representing 0.41% of the company's total share capital [4][8] - The purpose of this share reduction is attributed to Wang Haibo's personal funding needs, as stated in the previously announced reduction plan [3][4] Summary by Sections Section 1: Definition - The report defines key terms, including the information disclosure obligor (Wang Haibo) and the company (Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.) [2] Section 2: Information Disclosure Obligor - Wang Haibo is identified as the information disclosure obligor, with no other significant shareholdings in other listed companies [3] Section 3: Purpose of Equity Change - The equity change is primarily driven by Wang Haibo's funding needs, as outlined in a prior announcement regarding the reduction plan [3][4] Section 4: Method of Equity Change - Prior to the equity change, Wang Haibo held 56,099,327 shares (5.41% of total shares). After the reduction, he holds 51,828,605 shares (5.00%) [4][6] - The shares were sold between July 14 and July 15, 2025, through centralized bidding [4][8] Section 5: Trading History - There were no other transactions involving the company's shares by Wang Haibo in the six months preceding the report [5][8] Section 6: Other Significant Matters - The report confirms that all relevant information regarding the equity change has been disclosed accurately and completely [6][8]

Core Viewpoint - The announcement details a change in shareholding by major shareholder Wang Haibo, who has reduced his stake in Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. to 5% through a planned share reduction, which does not trigger a mandatory takeover bid [1][2]. Summary by Sections 1. Basic Information of the Shareholder - Wang Haibo is a Chinese national and holds permanent residency in Hungary [1]. 2. Details of the Shareholding Change - Wang Haibo reduced his shareholding from 56,099,327 shares (5.41%) to 51,828,605 shares (5.00%) by selling 4,270,722 shares through centralized bidding from July 14 to July 15, 2025 [1]. - The reduction in shareholding does not affect the control of the company as there is no controlling shareholder or actual controller [1][2]. 3. Shareholding Status Before and After the Change - Before the change: Wang Haibo held 56,099,327 shares (5.41% of total share capital) - After the change: Wang Haibo holds 51,828,605 shares (5.00% of total share capital) [1]. 4. Compliance with Regulations - The shareholding change complies with relevant regulations and does not violate any laws or guidelines regarding shareholder reductions [3].